In response to the first call for project proposals in 2007, the Center for Translational Molecular Medicine (CTMM) announced on April 1, 2008, that nine first-call projects would receive research funding amounting to a total of 150 million Euro. On March 10, 2009, it announced that eight new project proposals, submitted in the fall of 2008 in response to the second call for proposals, will receive funding amounting to a total of almost another 100 million Euro.
All Dutch university medical centers, plus several universities, a broad spectrum of small and medium-sized enterprises, major industry leaders including Philips and DSM, and the Dutch Government are involved.
The funding is provided by the Dutch government, industry and academia. The research is focused firmly on the ‘translational’ aspects of molecular medicine so that results can be applied as quickly as possible to actual patient care.
Musis is one of the projects from the second call with a total project budget of 9.2 M€, of which the Dutch government contributes 4.6 M€.
Societal benefits and healthcare savings
The improved surgical accuracy provided by NIRF imaging could be applied in a variety of patient groups, benefitting survival rates and quality of life.
In breast conserving surgery to treat breast cancer, the additional cost of NIRF imaging is more than outweighed by the reduced cost of secondary surgery. For sentinel lymph node removal, NIRF imaging costs are less than the cost of currently used imaging procedures that employ radioactive tracers.
In breast cancer care, NIRF imaging therefore increases QUALYs (quality-adjusted life years) and reduce costs.
Expected revenues: EUR 645 million in surgical oncology markets. Job creation in the Netherlands within 5 years: 50 in manufacturing, 15 in sales, 10 in business overhead.